Dr. Andreas Billich

Andreas Billich studied Chemistry at the University of M√ľnster, Germany, and received his Ph.D. in Biochemistry in 1985. As a PostDoc at the Technical University of West-Berlin he performed research on the biosynthesis of peptide antibiotics such as cyclosporin. In 1988 he joined the Sandoz (later Novartis) Research Institute in Vienna, Austria, where he worked on HIV targets such as protease and integrase. These studies on antivirals formed also the basis for his habilitation thesis, and Andreas received venia legendi for Biochemistry from the University of Vienna in 1996. Further work at Novartis Vienna as project and group leader focussed in the areas of dermatology and autoimmunity where he contributed, e.g., to the development of the MS-drug Gilenya. In 2008 he joined the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he continued preclinical research on autoimmune and inflammatory diseases, focussing on the S1P and IL-17 pathways. In 2019 he joined wings4innovation GmbH as Translational Guide.